Opioids are extensively used in patients with cancer pain; despite their efficacy, several
patients can experience ineffective analgesia and/or side effects. Pharmacogenetics is a …

Background Ivermectin, a substrate of multidrug resistance (MDR1) gene and cytochrome
P450 (CYP) 3A4, has been used successfully in the treatment of onchocerciasis in Ghana …

Human cell lines are often used for in vitro biotransformation and transport studies of drugs.
In vivo, genetic polymorphisms have been identified in drug-metabolizing enzymes and ABC …

For the treatment of cancer, the window between drug toxicity and suboptimal therapy is
often narrow. Interindividual variation in drug metabolism therefore complicates therapy …

Aims Tacrolimus is a critical dose drug and to avoid under‐and overexposure, therapeutic
drug monitoring is standard practice. However, rejection and drug‐related toxicity occur …

Background: Tacrolimus metabolism depends on CYP3A4 and CYP3A5. We aimed to
determine the relationship between the CYP3A4* 22 polymorphism and combined CYP3A …

Tamoxifen is a pro-drug widely used in breast cancer patients to prevent tumor recurrence.
Prior work has revealed a role of cytochrome and sulfotransferase enzymes in tamoxifen …

Purpose The once daily formulation of tacrolimus is an important immunosuppressive drug.
Interpatient variability in metabolism has been related to genetic variation in CYP3A4 and …

Summary Background: Calcineurin inhibitor (cyclosporine, CsA) and mTOR inhibitors
(sirolimus, SRL)–immunosuppressants used to prevent allograft rejection after renal …

Background and objective: The drug transporter MDR1 and the drug metabolizing enzyme
CYP3A are the two major biological factors determining the pharmacokinetics of many …